<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366199">
  <stage>Registered</stage>
  <submitdate>19/04/2014</submitdate>
  <approvaldate>30/04/2014</approvaldate>
  <actrnumber>ACTRN12614000444684</actrnumber>
  <trial_identification>
    <studytitle>Evaluation of the Pharmacokinetics of Sublingual IPX237 in Healthy Volunteers</studytitle>
    <scientifictitle>IPX237-B14-01: Evaluation of the Pharmacokinetics of Sublingual IPX237 in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Depression</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single-center, open-label, randomized, single-dose, 4-sequence, 4-treatment crossover study with at least 5 days of washout between dosing in each treatment period.
Subjects will be randomized to one of four sequences to receive the following investigational treatments under fasted condition:  
Treatment A: IPX237-L0003 sublingual paste (0.42 mL)90 mg, retained under the tongue for 2 minutes.
Treatment B: IPX237-L0003 sublingual paste (0.42 mL) 90mg,  no restriction on retention or swallowing.
Treatment C: IPX237-L0002 sublingual paste (0.42 mL)45mg,   retained under the tongue for 2 minutes.
Treatment D: 15 mg esketamine (free base equivalent), preservative-free, infused IV over 40 minutes.
The sublingual paste must be placed under the tongue using the prefilled applicator.  Proper administration of the sublingual drug products should be confirmed by a mouth check. Subjects must not expectorate, drink, or rinse the mouth for at least 1 hour postdose.
The subject should be evaluated at 32 hours postdose to determine that they are medically stable.  The subject should be driven home by a responsible adult. </interventions>
    <comparator>Treatment D: 15 mg esketamine (free base equivalent)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pharmacokinetics</outcome>
      <timepoint>During each treatment period, blood samples will be collected for measurement of esketamine and (S)-norketamine in plasma at the following times: within 60 minutes predose, and postdose at 10, 20, 30, 40, and 50 minutes and  1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety</outcome>
      <timepoint>12-lead electrocardiograms (ECG), clinical laboratory tests, vital signs, adverse events (AEs), and concomitant medications will be evaluated over the course of the study.  Physical examinations will be performed at Screening and at Study Exit.  Single ECG will be evaluated at Screening, predose, and at 45 minutes, and 8 hours postdose.  Vital signs will be measured in each period as specified. </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers between the ages of 18 and 55 years of age inclusive, weighing at least 60 kg with BMI of 18.0 kg/m2 to 29.5 kg/m2 (inclusive) at the time of informed consent.  </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Presence of a clinically significant disorder, including acute or chronic infections or a malignant neoplasm and/or involving disease in one or more of these organ systems: cardiovascular, respiratory, renal, gastrointestinal, immunologic, musculoskeletal, hematologic, dermatologic, hepatic, reproductive, endocrine, or neurologic/psychiatric, as determined by clinical investigators. 
History of psychosis in self or family.  
History of or clinical signs of glaucoma.  
History of or clinical signs of any form of epilepsy or seizures</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/07/2014</anticipatedstartdate>
    <actualstartdate>8/07/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate>12/08/2014</actualenddate>
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Impax Pharmaceuticals,A Division of Impax Laboratories, Inc.</primarysponsorname>
    <primarysponsoraddress>31047 Genstar Road Hayward, CA 94544</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Impax Laboratories, Inc</fundingname>
      <fundingaddress>30831 Huntwood Avenue Hayward, CA 94544</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To characterize the pharmacokinetics (PK), safety, and tolerability of sublingually administered esketamine hydrochloride from IPX237 at two dose strengths, and to evaluate the effect of formulation retention in the sublingual space.</summary>
    <trialwebsite />
    <publication>N/A</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bellberry Human Research Ethics Committee</ethicname>
      <ethicaddress>71 Anzac Highway Ashford, SA 5035  </ethicaddress>
      <ethicapprovaldate>6/06/2014</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>14/05/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Guy Ludbrook</name>
      <address>CMAX, a division of IDT Australia Limited Level 5 East Wing Royal Adelaide Hospital North Terrace Adelaide, SA 5000</address>
      <phone>+61 8 8222 5422</phone>
      <fax />
      <email>guy.ludbrook@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Teo Franic </name>
      <address>Level 5 East Wing Royal Adelaide Hospital North Terrace Adelaide SA 5000</address>
      <phone>61 8 8222 3923</phone>
      <fax />
      <email>Teo.franic@cmax.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Guy Ludbrook</name>
      <address>CMAX, a division of IDT Australia Limited Level 5 East Wing Royal Adelaide Hospital North Terrace Adelaide, SA 5000</address>
      <phone>+61 8 8222 5422</phone>
      <fax />
      <email>guy.ludbrook@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>